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Sudden cardiac death (SCD) remains a leading
cause of mortality worldwide. In the United States,
deaths attributed to SCD are estimated at 310,000
per year, overwhelmingly as a result of ventricular
tachyarrhythmias (VT) [1]. Heart failure (HF) rep-
resents the most common substrate for VT; and the
risks of these arrhythmias, as well as of SCD, in-
crease as ejection fraction decreases among pa-
tients with both ischemic and non ischemic heart
disease. The substrate for malignant VT is facilitated
by fibrosis and dilation that occur in these diseased
states. This potential electrical instability can be
further triggered and exacerbated by sympathetic
excitation in the presence of congestive HF [2–4].
The incidence, prevalence and mortality rate of HF
are all known to increase with advancing age. Those
75 to 84 years of age have double the annual rates of
HF events as compared with those 65 to 74 years of
age, and those older than 85 have four-fold annual
rates of HF events as compared with those aged
65 to 74. The prevalence of HF is 2–3% in the total po-
pulation, but in those older than 75 it rises to 10–20%
[5, 6]. In patients with HF, their one-year mortali-
ty rate increases by 60% to 70% per decade [7, 8].
To date, multiple randomized clinical trials
have demonstrated a significant reduction in the
risk of death with an implantable cardioverter-
-defibrillator (ICD) among patients with a left ven-
tricular ejection fraction < 30–40% [9–13]. How-
ever, the patient population enrolled in these stu-
dies consisted mainly of young patients, with a mean
age of 52–64 years, and data on the benefit of ICDs
among older age groups remains limited and at
times controversial. The effects of older age on ICD
benefit could be potentially related to two oppos-
ing factors: (1) elderly patients have more co-mor-
bidities than their younger counterparts, thus, the
proportion of patients dying due to VT and SCD de-
creases with advancing age; and (2) the incidence,
prevalence and mortality rate of HF increase with
advancing age, so that any proven beneficial thera-
py (e.g. ICD implantation) in patients with HF might
be associated with a greater survival benefit in this
population.
In their article in this issue of Cardiology Jour-
nal, Kong et al. [14] report the results of a meta-
analysis investigating the effectiveness of ICD
among patients aged over 65 and among patients
aged over 75. Their meta-analysis focused on the
five studies that are considered most relevant to
primary prevention ICD therapy, namely MADIT
(Multicenter Automatic Defibrillator Implantation
Trial) [9], MUSTT (Multicenter Unsustained Ta-
chycardia Trial) [10], MADIT-II [11], DEFINITE
(Defibrillators in Non-Ischemic Cardiomyopathy
Treatment Evaluation) [12], and SCD-HeFT (Sud-
den Cardiac Death in Heart Failure Trial) [13].
Many of these trials did not include a pre-defined
age limit. Primary prevention ICD therapy was as-
sociated with a significant 40% reduction (95% con-
fidence interval [CI] 22–55%) in all-cause mortali-
ty among patients ≥ 65 years old and with a signi-
ficant 27% (95% CI 3–49%) reduction in all-cause
mortality among patients ≥ 75 years old. Similar
results were found when the MUSTT trial, where
ICD therapy was not randomized, was excluded. It
should be noted that the authors excluded five other
randomized clinical trials: CAT (Cardiomyopathy
Trial) and AMIOVIRT (Amiodarone Versus Im-
plantable Cardioverter Defibrillator Trial) which
were small studies that were excluded due to lack
of estimates of ICD effect based on age; and DINAMIT
(Defibrillator in Acute Myocardial Infarction Trial),
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CABG-PATCH, and IRIS (Immediate Risk Stratifi-
cation Improves Survival) which enrolled patients
early post-myocardial infarction or coronary artery
bypass grafting (i.e. patients not included in the cur-
rent guidelines for primary prevention ICD).
Moreover, the authors provided a comprehen-
sive review of the literature and summarized the
results of substudies and non-randomized trials in-
vestigating the effectiveness of ICD among older
patients. The authors showed consistent results
demonstrating that primary prevention ICD among
high risk older patients (≥ 65 or ≥ 75 years) is asso-
ciated with greater survival rates, but not associa-
ted with significantly increased risk for procedural
or post-procedural complications. Importantly, the
authors also attempted to address the question as to
whether ICDs affect quality of life differently among
older and younger patients. Although they found only
limited data, older patients did not experience a sig-
nificant decrease in quality of life.
The overall beneficial effects of primary ICD
implantation in the older age groups as shown in this
meta-analysis and review of literature, however,
should be interpreted with caution due to the fol-
lowing limitations: (1) analysis of data on elderly
patients enrolled in randomized control trials might
not reflect ‘real world’ practice, as very high risk
elderly patients with multiple co-morbidities, par-
ticularly with advanced renal dysfunction, are often
excluded from ICD randomized control trials; (2) gi-
ven the low number of octogenarians and nona-
genarians enrolled in these studies, conclusions
could not be made for these important, and grow-
ing, subgroups of patients; (3) the current meta-
-analysis provides data on the effect of old age on
ICD benefit by employing mainly univariate analy-
ses; to explore the effectiveness of ICD among
young and elderly patients, it is important to neu-
tralize the effects of co-morbid conditions by adjust-
ing for clinical variables or by setting sudden car-
diac death as the primary end point instead of all-
cause mortality; (4) intrinsic inadequacies of
a meta-analysis should be realized and applied to
the interpretation of the analyzed data.
The importance of risk factors and co-morbidi-
ties for the assessment of ICD effectiveness was
previously shown in a MADIT-II substudy [15],
where five simple clinical parameters (comprising
age, heart failure functional class, blood urea nitro-
gen, QRS duration, and atrial fibrillation) were found
to stratify patients into a low-risk group (with none
of the five clinical risk factors) who did not derive
a significant survival benefit from the ICD; an in-
termediate-high risk group (≥ one risk factors) who
derived a pronounced benefit from primary ICD im-
plantation; and a very high risk group (with advanced
comorbidities), in whom the benefit of the ICD was
attenuated. Although Kong et al. [14] have provided
data from substudies of clinical trials showing that
by multivariate analyses the effects of age on ICD
benefit were consistent with the main results of the
univariate results of the meta-analysis, it should be
noted that the variables included in each substudy
model are different, and thus it is difficult to evalu-
ate the overall isolated effect of age on ICD benefit.
In trials assessing medical therapy, the derived
benefits from the study medication may only be ex-
pected if ’targeted’ dosing is applied and proper pa-
tients are selected. One may not extrapolate the data
to lower doses or in improperly selected patients.
The same principle should be remembered in pa-
tients being considered for device therapy, especially
one as expensive as ICD. Inclusion and exclusion cri-
teria incorporated in these studies need to be kept
in mind when clinical decisions for device therapy
are made.
Until there is randomized data on the effective-
ness of ICD as primary prevention therapy in eld-
erly patients, the debate about the risk/benefit ba-
lance is sure to persist. The existing guidelines for
ICD therapy may well prevent such trials from be-
ing carried out, as it may be difficult to justify with-
holding device therapy in the control group. The
cost issues of such therapy in this population are
also critical subjects that societies need to ponder;
in many regions in the world, the expenses related
to the therapy alone are prohibitive.
Within these confines, the current study adds
to the accumulating data showing that age does not
attenuate the benefit of ICD therapy, thus support-
ing the opinion that appropriate risk assessment
before ICD implant among appropriately selected
patients should not be withheld from the elderly pa-
tients based on age alone.
Acknowledgements
The authors have no conflicts of interest to
declare.
References
1. Roger VL, Go AS, Lloyd-Jones DM et al. Heart disease and
stroke statistics 2011 update: A report from the American Heart
Association. Circulation, 2011; 123: e18–e209.
2. Pogwizd SM, Hoyt RH, Saffitz JE, Corr PB, Cox JL, Cain ME.
Reentrant and focal mechanisms underlying ventricular tachy-
cardia in the human heart. Circulation, 1992; 86: 1872–1887.
475
Alon Barsheshet, David T. Huang, ICD therapy in the elderly
www.cardiologyjournal.org
3. de Bakker JM, van Capelle FJ, Janse MJ et al. Reentry as a cause
of ventricular tachycardia in patients with chronic ischemic heart
disease: Electrophysiologic and anatomic correlation. Circula-
tion, 1988; 77: 589–606.
4. Hamdan MH, Zagrodzky JD, Joglar JA et al. Biventricular pacing
decreases sympathetic activity compared with right ventricular
pacing in patients with depressed ejection fraction. Circulation,
2000; 102: 1027–1032.
5. Dickstein K, Cohen-Solal A, Filippatos G et al. ESC Guidelines for
the diagnosis and treatment of acute and chronic heart failure 2008:
The Task Force for the Diagnosis and Treatment of Acute and
Chronic Heart Failure 2008 of the European Society of Cardiology.
Developed in collaboration with the Heart Failure Association of
the ESC (HFA) and endorsed by the European Society of Intensive
Care Medicine (ESICM). Eur Heart J, 2008; 29: 2388–2442.
6. Mosterd A, Hoes AW. Clinical epidemiology of heart failure.
Heart, 2007; 93: 1137–1146.
7. Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV. Predic-
ting mortality among patients hospitalized for heart failure: Deriva-
tion and validation of a clinical model. JAMA, 2003; 290: 2581–2587.
8. Siirila-Waris K, Lassus J, Melin J et al. Characteristics, out-
comes, and predictors of 1-year mortality in patients hospita-
lized for acute heart failure. Eur Heart J, 2006; 27: 3011–3017.
9. Moss AJ, Hall WJ, Cannom DS et al. Improved survival with an
implanted defibrillator in patients with coronary disease at high
risk for ventricular arrhythmia. Multicenter Automatic Defibril-
lator Implantation Trial Investigators. N Engl J Med, 1996; 335:
1933–1940.
10. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN,
Hafley G. A randomized study of the prevention of sudden death
in patients with coronary artery disease. Multicenter Unsus-
tained Tachycardia Trial Investigators. N Engl J Med, 1999; 341:
1882–1890.
11. Moss AJ, Zareba W, Hall WJ et al. Prophylactic implantation of
a defibrillator in patients with myocardial infarction and reduced
ejection fraction. N Engl J Med, 2002; 346: 877–883.
12. Kadish A, Dyer A, Daubert JP et al. Prophylactic defibrillator
implantation in patients with nonischemic dilated cardiomyopa-
thy. N Engl J Med, 2004; 350: 2151–2158.
13. Bardy GH, Lee KL, Mark DB et al. Amiodarone or an implanta-
ble cardioverter-defibrillator for congestive heart failure. N Engl
J Med, 2005; 352: 225–237.
14. Kong MH, Al-Khatib SM, Sanders GD, Hasselblad V, Peterson ED.
Use of implantable cardioverter-defibrillators for primary pre-
vention in older patients: A systematic literature review and
meta-analysis. Cardiol J, 2011; 18: 503–514.
15. Goldenberg I, Vyas AK, Hall WJ et al. Risk stratification for
primary implantation of a cardioverter-defibrillator in patients
with ischemic left ventricular dysfunction. J Am Coll Cardiol,
2008; 51: 288–296.
